The wide spectrum of multidrug resistance 3 deficiency: From neonatal cholestasis to cirrhosis of adulthood

Gastroenterology

Volumn 120, Issue 6, 2001, Pages 1448-1458

  Jacquemin, Emmanuel ^a   DeVree, J Marleen L ^b   Cresteil, Danièle ^a   Sokal, Etienne M ^d   Sturm, Ekkehard ^e   Dumont, Micheline ^f   Scheffer, George L ^c   Paul, Marianne ^b   Burdelski, Martin ^e   Bosma, Piter J ^b   Bernard, Olivier ^a   Hadchouel, Michelle ^a   Oude Elferink, Ronald P J ^b  

^a BICÊTRE HOSPITAL   (France)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ISOPROTEIN; MULTIDRUG RESISTANCE PROTEIN; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; ARTICLE; BILIARY CIRRHOSIS; CHILD; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FRAMESHIFT MUTATION; GALLSTONE; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; INTRAHEPATIC CHOLESTASIS; LIVER HISTOLOGY; MALE; MISSENSE MUTATION; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SEQUENCE ANALYSIS;

EID: 0035045719     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.23984     Document Type: Article

References (43)

1. Byler disease: Fatal familial intrahepatic cholestasis in an Amish kindred
2. Byler's disease: Fatal intrahepatic cholestasis
3. Clinical and biochemical findings in progressive familial intrahepatic cholestasis
4. Progressive familial cholestatic cirrhosis and bile acid metabolism
5. Evidence for defective primary bile acid secretion in children with progressive familial intrahepatic cholestasis (Byler disease)
6. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): Evidence for heterogeneity
7. 4-3 oxosteroid 5β-reductase deficiency described in identical twins with neonatal hepatitis. A new inborn error in bile acid synthesis
8. 27-steroid dehydrogenase/isomerase deficiency
9. Molecular pathogenesis of cholestasis
10. Intrahepatic cholestasis: Order out of chaos
11. Genetic basis of progressive familial intrahepatic cholestasis
12. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis
13. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis
14. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis
15. Normal serum gamma-glutamyl-transpeptidase activity identifies groups of infants with idiopathic cholestasis with poor prognosis
16. Histologic pathology of the liver in progressive familial intrahepatic cholestasis
17. Diagnostic value of serum g-glutamyl transpeptidase activity in liver diseases in children
18. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis
19. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease
20. Phosphatidylcholine translocase: A physiological role for the mdr2 gene
21. Tissue distribution of the human MDR3 P-glycoprotein
22. Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidycholine excretion absent in mdr2 (-/-) mice
23. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis
24. Ursodeoxycholic therapy in pediatric patients with progressive familial intrahepatic cholestasis
25. Structure of the human MDR3 gene and physical mapping of the human MDR locus
26. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy
27. Biliary lipid composition in healthy and diseased infants, children, and young adults
28. Class III P-glycoproteins mediate the formation of lipoprotein X in the mouse
29. CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells
30. Genetic analysis of the multidrug transporter
31. Mutations in the nucleotide-binding sites of P-glycoprotein that affect substrate specificity modulate substrate-induced adenosine triphosphatase activity
32. Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites
33. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein
34. Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12
35. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome
36. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: Evidence for a defect in protein trafficking
37. Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein
38. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
39. Functional characterization of missense mutations in ATP7B: Wilson disease mutation or normal variant?
40. Copper storage disease: Wilson disease or familial cholestasis
41. Effects of ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 p-glycoprotein gene
42. MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping
43. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis